Shot in the arm for GSK and AstraZeneca from cancer drug sales
The blue chip drug makers saw first quarter earnings beat market expectations.

Source: The Independent
The blue chip drug makers saw first quarter earnings beat market expectations.
The blue chip drug makers saw first quarter earnings beat market expectations.

Source: The Independent